Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,119.02
(
-0.77%
)
US TECH 100
26,190.00
(
-1.43%
)
Dow Jones
49,165.69
(
-0.29%
)
Brent Oil
104.21
(
2.05%
)
Bitcoin
76,133.28
(
-1.60%
)
News Focus
News Focus
Post# of 257457
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122896
Boards Moderated 9
Alias Born 09/05/2002

DewDiligence

Member Level

Re: dewophile post# 252379

Wednesday, 06/26/2024 4:48:17 PM

Wednesday, June 26, 2024 4:48:17 PM

Post# of 257457

The first patients eligible for revaccination won’t happen until the 2025-2026 season so there was no urgency here. I’m still assuming annual for MRNA amd biennial for GSK/PFE.

I concur. If MRNA’s mResvia had been approved in time for the 2023-2024 RSV season, ACIP probably would have had to address the re-vaccination schedule at today’s meeting. However, mResvia FDA approval only one month ago allowed ACIP to kick the can down the road.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today